Keyword: Flublok

Dupixent grew sales by 28% sequentially at constant currencies, to €225 million, and that doesn't even count a recent major approval in asthma.

As Sanofi mobilizes millions of flu shots, it's working with the American Lung Association to make sure vaccines get to the people who need them.

Seqirus published data showing that cell-derived flu viruses matched better with circulating strains than egg-based counterparts.

Sanofi will increase the supplies of Flublok Quadrivalent and Fluzone High-Dose to 25 million doses for the coming flu season.

Seqirus' cell-based flu vaccine was 26.5% effective at keeping those 65 and older out of the hospital in the past flu season, an FDA study finds.

Sanofi raised the price of Flublok by 12.5% last year, its only increase above the U.S. National Health Expenditure growth rate.

Sanofi's net prices fell 8.4% last year, the drugmaker reported in an update to its pricing policies.

The licensing deal provides Sanofi Pasteur access to a cell culture technology for use in its universal influenza vaccine.

Not long after its acquisition by Sanofi, Protein Sciences is bidding adieu to its former leader.